超全或完全切除后胶质母细胞瘤IDH野生型极端生存组的分子特征
该回顾性研究分析了2009至2025年间接受超全或完全强化灶切除的85例新诊断IDH野生型胶质母细胞瘤患者,比较短期生存(≤12个月)、非短期生存(>12个月)和长期生存(≥36个月)组的临床、影像和分子特征。结果显示短期生存者占28%,长期生存者占18.8%,CDKN2A/B缺失和EGFR扩增在短期生存者中更常见。
要点
- 超全或完全切除后短期生存者仍占约28%,长期生存者仅约18.8%。
- CDKN2A/B缺失和EGFR扩增可能与术后生存缩短相关。
- 非局部复发对短期生存的影响尚不确定。
核心结论
- 尽管行超全或完全强化灶切除,IDH野生型胶质母细胞瘤短期生存者仍占约28%,生存超过3年者仅约18.8%。
- CDKN2A/B缺失和EGFR扩增可能与超全或完全切除后生存缩短相关。
研究设计与样本
- 回顾性分析2009至2025年在本机构接受超全或完全强化灶切除并接受下一代测序的新诊断IDH野生型胶质母细胞瘤患者。
- 共纳入85例患者,分为短期生存(生存≤12个月)、非短期生存(生存>12个月)和长期生存(生存≥36个月)组。
主要发现
- 85例患者中24例(28%)为短期生存者,61例为非短期生存者,其中16例(18.8%)为长期生存者。
- 短期生存者额叶肿瘤较多(45.8%),长期生存者颞叶肿瘤较多(62.5%)。
- 短期生存者非局部复发率有增高趋势(27.2%),但无统计学显著性。
临床怎么用
- 对于IDH野生型胶质母细胞瘤,即使实现超全或完全强化灶切除,仍需关注CDKN2A/B缺失和EGFR扩增等分子标志以评估生存风险。
局限性
- 本研究为单中心回顾性分析,样本量有限(85例),非局部复发对短期生存的影响尚不确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Glioblastoma (GBM) isocitrate dehydrogenase-wildtype remains a devastating brain tumor with a poor prognosis despite optimal treatment. Even after supramaximal or complete contrast-enhancing (CE) resection, patient outcomes vary significantly, with some experiencing short-term survival (STS) and others long-term survival (LTS). This study aims to identify clinical and molecular markers predicting the survival of patients with GBM in these high-resection categories. METHODS: We retrospectively analyzed patients with newly diagnosed GBM who underwent supramaximal or complete CE resection, followed by next-generation sequencing at our institution (2009-2025). Patients were categorized as STS (survival ≤12 months), non-STS (survival >12 months), or LTS (survival ≥36 months). We compared clinical, radiological, and molecular features between these groups to identify potential prognostic markers. RESULTS: Among 85 patients who met the inclusion criteria, 24 (28%) were STSs and 61 were non-STS (from which 16 [18.8%] were LTSs), with no significant molecular differences observed between these groups. On comparing STS and LTS patients, CDKN2A/B loss (83.3% vs 43.8%, P = .01) and EGFR amplification (58.3% vs 25%, P = .05) were more frequent in STS patients vs LTS. Tumor location varied, with STS patients having more frontal lobe tumors (45.8%) and LTS patients having more temporal lobe tumors (62.5%). A trend, although not statistically significant, toward increased nonlocal recurrence rates was observed in STS patients (27.2%). CONCLUSION: Despite aggressive extent of resection in GBM, the prevalence of STS patients remains notable at ∼28% and survival beyond 3 years remains limited at ∼18.8%. CDKN2A/B loss and EGFR amplification might correlate with shortened survival after supramaximal or complete CE resection. The impact of nonlocal recurrence remains uncertain among STSs. These findings highlight the need for collaborative studies to advance understanding of the biology of GBM as their behavior differs despite aggressive surgical and medical therapies.
引用
- Bueno A, Dono A, Amezquita-Contreras C, et al. Molecular Features of Glioblastoma Isocitrate Dehydrogenase-Wildtype in Extreme Survival Groups After Supramaximal and Maximal Resection. Neurosurgery. 2026. PMID: 41589891. doi:10.1227/neu.0000000000003929
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。